Head to Head Review: Brickell Biotech (BBI) vs. The Competition
Brickell Biotech (NASDAQ: BBI) is one of 156 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it contrast to its peers? We will compare Brickell Biotech to similar companies based on the strength of its risk, institutional ownership, dividends, valuation, analyst recommendations, profitability and earnings.
This table compares Brickell Biotech and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Brickell Biotech Competitors||-3,860.46%||-95.08%||-41.21%|
Brickell Biotech has a beta of -0.11, indicating that its share price is 111% less volatile than the S&P 500. Comparatively, Brickell Biotech’s peers have a beta of 1.28, indicating that their average share price is 28% more volatile than the S&P 500.
Institutional and Insider Ownership
13.2% of Brickell Biotech shares are held by institutional investors. Comparatively, 51.6% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 10.3% of Brickell Biotech shares are held by company insiders. Comparatively, 17.7% of shares of all “Biological products, except diagnostic” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Earnings & Valuation
This table compares Brickell Biotech and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Brickell Biotech||$7.92 million||-$23.88 million||-0.16|
|Brickell Biotech Competitors||$693.87 million||$123.86 million||-4.63|
Brickell Biotech’s peers have higher revenue and earnings than Brickell Biotech. Brickell Biotech is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
This is a breakdown of current recommendations and price targets for Brickell Biotech and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Brickell Biotech Competitors||1494||4524||9001||405||2.54|
Brickell Biotech presently has a consensus price target of $5.50, suggesting a potential upside of 574.85%. As a group, “Biological products, except diagnostic” companies have a potential upside of 28.15%. Given Brickell Biotech’s stronger consensus rating and higher probable upside, analysts clearly believe Brickell Biotech is more favorable than its peers.
Brickell Biotech peers beat Brickell Biotech on 8 of the 13 factors compared.
Brickell Biotech Company Profile
Brickell Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of various prescription therapeutics for the treatment of debilitating skin diseases in the United States. The company's lead products candidate is sofpironium bromide that is in Phase III clinical trial for patients with axillary hyperhidrosis. It is also developing therapeutics for cutaneous T-cell lymphoma, psoriasis, and other dermatological conditions. The company was founded in 2009 and is based in Boulder, Colorado.
Receive News & Ratings for Brickell Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brickell Biotech and related companies with MarketBeat.com's FREE daily email newsletter.